Welcome to BioSeeker Group!

Ion Channel Drug Discovery - Therapeutic Opportunities and Technology Progress

Additional Information

Published Date May 11, 2004
Pages 189
PDF Fact Sheet View Fact Sheet for the report Ion Channel Drug Discovery - Therapeutic Opportunities and Technology Progress in PDF
Format PDF
Publisher BioSeeker Group

Availability: In stock

$999.00

Quick Overview

In this report, BioSeeker Group has identified and analyzed advancements in novel, ion-channel targeted drug development as well as technology breakthroughs.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Ion Channel Drug Discovery - Therapeutic Opportunities and Technology Progress.

    To find out more about Ion Channel Drug Discovery - Therapeutic Opportunities and Technology Progress, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Ion Channel Drug Discovery - Therapeutic Opportunities and Technology Progress is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Executive Summary

Increased knowledge of novel targets in combination with a strong progress in drug discovery technologies has strongly contributed to the fast development in ion channel drug discovery that we are witnessing today. This progress is helping to pave the way for immense commercial opportunities. In this report, BioSeeker Group has identified and analyzed advancements in novel, ion-channel targeted drug development as well as technology breakthroughs.

During the last two years a vast amount of commercial data has been presented, which clearly implies that this is a field on the move. The report "Ion Channel Drug Discovery - Therapeutic Opportunities & Technology Progress" will provide you with the foundation needed to study this field further.

Ion channels play significant role in a great number of cell types and occur as large families of related genes with cell-specific expression patterns. Progress in transcription profiling is revealing the tissue specific distributions of ion channels. Further, many common diseases, such as cardiac arrhythmias, diabetes, hypertension, angina pectoris and epilepsy, have been related to dysfunction of ion channels. Considering this in combination with the access to the human genome, ion channels will most probably play a much more important role as therapeutic drug targets in the future.

One of the major difficulties faced by drug discovery companies has been to screen for compounds interacting with ion channels in an efficient manner. The last two years have resulted in important development of the current screening techniques, and as a result it is possible that we will witness a breakthrough for the ion channel drug discovery within a few years time.

BioSeeker Group has recognized the demand for a continuous surveillance within the field of ion channels as targets for drug discovery. We have also surveyed and investigated the development of new ion channel screening assays - an equally important and much requested aspect of ion channel drug discovery. This report analyzes the technical development of ion channel drug screening techniques such as ion- flux-, patch-clamping, patch-on-a-chip and high-throughput assays. Moreover, it will provide you with an in-depth review of the current targets and drugs in ion channel R&D in both pre-clinical and clinical developmental stage. The report will also provide you with information about key alliances behind the progress.

The report consists of +189 pages, including +50 companies with corporate descriptions. To assist you in grasping the material in the report we have generated various illustrative tables and figures.

Companies Included in the Report

Abbott Laboratories, Able Laboratories, Agis Industries Ltd., Akorn, Inc., ALA Scientific Instruments Inc., American Pharmaceutical Partners, Andrx Corporation, Apotex Inc., AstraZeneca, Athena Neurosciences, Aurora Biosciences, Aurora Biomed Inc., Aventis Pharmaceuticals Inc., AVIVA Biosciences Corporation Inc., Axon Instruments, Barr Laboratories, Bayer, BioChip, Biofocus, Bioniche Life Sciences Inc., Biovail, Bradley Pharmaceuticals, Cardiome Pharma Corp, Cellectricon, Celltech Group PLC., Central Research Laboratories Limited (CRL), ChanTest, CeNeS Pharmaceuticals Inc., Cortex, Dentsply International Inc., Cytocentrics, Cytoplex Biosciences, Devgen, Elan Corporation PLC, Eli Lilly and Company, Endo Pharmaceuticals Holdings Inc., Fougera, Flyion, GlaxoSmithKline, IMPAX Laboratories Inc., IOMED, Johnson & Johnson, KV Pharmaceutical Company, Lannett Company Inc., Mayne Pharma USA Inc., Merck KGaA, Molecular Devices, Morton Grove Pharmaceuticals Inc.,Multi Channel Systems, Mylan Laboratories Inc., Nanion Technologies, Neurion Pharmaceuticals Inc, Neurosearch, NexMed, Nissan Chemical Industries Ltd., Novartis Pharmaceuticals Corporation, Orion Pharma, Oryx Pharmaceuticals Inc., Parke-Davis, Pfizer Inc., Ranbaxy Laboratories, Scion Pharmaceutical, Sanofi-Synthelabo, Sophion Bioscience Taro Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, Vernalis plc., Wyeth and Xcel Pharmaceuticals.

Executive Summary

Methodology
Information Sources

Introduction
Drug Screening Technologies
Direct Assays
Indirect Assays
What Can Be Measured?
Scientific Summary
Introduction: Ion Channels And Disease
Table 1. The Relationship Of Ion Channels And Disease
Autoimmune And Inflammatory Diseases
Metabolic And Endocrinological Diseases
Oncology
Neurological Diseases
Cardiology Diseases
Cardiovascular Diseases

New Discoveries
Technology Platforms
Ion-Flux Assays
Patch-Clamp
Table 2. The Patchxpress 700a
High Throughput Screens
New Drug Discovery Technology Platforms
Key Alliances
Table 3. Alliances Between Ion Channel Technology And Drug Discovery Companies
Patents
Ion Channel Assay Market Outlook
Conclusion
The Ion Channel Drug Market
The Importance Of Ion Channel Technologies In Drug Discovery
Fig. 1. Distribution Of Companies Currently Active In Ion Channel Drug Discovery.
Fig 2. The Relationship Between Different Drugs And Disease Type.
Table 4. Drugs On The Market (Company, Drug, Indication And Target)
Collaborations
Table 5. The Collaborative Landscape.
Novel Ion Channel Targeting Drugs In Development
Table 6. Close To 70 Drug Candidates Have Been Identified.
Acid Related Gastrointestinal Disease
Chronic Obstructive Pulmonary Disease And Rheumatoid Arthritis
Cns Related Diseases
Table 7. Drug Candidates In Different Development Stages For The Treatment Of Cns Related Diseases (Companies, Drugs, Targets, Diseases And Developmental Stage).
Cancer
Cardiovascular
Diabetes
Osteoarthritis
Overactive Bladder
Collaborations
Discovery Of Novel Ion Channels Will Increase The Current Drug Portfolio In The Future
Table 8. Novel Ion Channel Targets.
Patents
Conclusion
Ion Channel Drug Discovery Market Outlook
Selected Company Profiles
Technology Companies
Pharmaceutical Companies

Appendix
Appendix I, Patents Related To Ion Channel Antagonists
Appendix Ii, Patents Related To Ion Channel Modulators (Other)
Appendix Iii, Patents Related To Ion Channel Agonists
Appendix Iv, Patents Related To Ion Channel Assay Technology

Disclaimer
Liability
Completeness

Abbott Laboratories, Able Laboratories, Agis Industries Ltd., Akorn, Inc., ALA Scientific Instruments Inc., American Pharmaceutical Partners, Andrx Corporation, Apotex Inc., AstraZeneca, Athena Neurosciences, Aurora Biosciences, Aurora Biomed Inc., Aventis Pharmaceuticals Inc., AVIVA Biosciences Corporation Inc., Axon Instruments, Barr Laboratories, Bayer, BioChip, Biofocus, Bioniche Life Sciences Inc., Biovail, Bradley Pharmaceuticals, Cardiome Pharma Corp, Cellectricon, Celltech Group PLC., Central Research Laboratories Limited (CRL), ChanTest, CeNeS Pharmaceuticals Inc., Cortex, Dentsply International Inc., Cytocentrics, Cytoplex Biosciences, Devgen, Elan Corporation PLC, Eli Lilly and Company, Endo Pharmaceuticals Holdings Inc., Fougera, Flyion, GlaxoSmithKline, IMPAX Laboratories Inc., IOMED, Johnson & Johnson, KV Pharmaceutical Company, Lannett Company Inc., Mayne Pharma USA Inc., Merck KGaA, Molecular Devices, Morton Grove Pharmaceuticals Inc.,Multi Channel Systems, Mylan Laboratories Inc., Nanion Technologies, Neurion Pharmaceuticals Inc, Neurosearch, NexMed, Nissan Chemical Industries Ltd., Novartis Pharmaceuticals Corporation, Orion Pharma, Oryx Pharmaceuticals Inc., Parke-Davis, Pfizer Inc., Ranbaxy Laboratories, Scion Pharmaceutical, Sanofi-Synthelabo, Sophion Bioscience Taro Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, Vernalis plc., Wyeth and Xcel Pharmaceuticals.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Ion Channel Drug Discovery - Therapeutic Opportunities and Technology Progress.
    To find out more about Ion Channel Drug Discovery - Therapeutic Opportunities and Technology Progress, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Ion Channel Drug Discovery - Therapeutic Opportunities and Technology Progress is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Drug Discovery' category:


Promising Drug Discovery Tools in Antifungal and Status on Emerging Novel Targets
This report will give you a comprehensive overview of the emerging novel drug targets as well as the new generation of antifungal drugs in clinical trials. Learn More


Ion Channel Drug Discovery - Therapeutic Opportunities and Technology Progress
In this report, BioSeeker Group has identified and analyzed advancements in novel, ion-channel targeted drug development as well as technology breakthroughs. Learn More